Indivior Pharmaceuticals, Inc. INDV Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net revenue by Product | ||||||
| PERSERIS | $5M+25.0% | $5M-44.4% | $6M-25.0% | $8M-38.5% | $4M-63.6% | |
| Sublingual & other | $50M-7.4% | $69M+11.3% | $51M-16.4% | $52M-17.5% | $54M-14.3% | |
| SUBLOCADE | $232M+31.8% | $252M+29.9% | $219M+14.7% | $209M+8.9% | $176M-1.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Indivior Pharmaceuticals, Inc. break its business down?
- Indivior Pharmaceuticals, Inc. (INDV) reports net revenue by product across 3 parts — PERSERIS, Sublingual & other and SUBLOCADE. Each is extracted from the segment footnotes and tracked over time.
- Where does Indivior Pharmaceuticals, Inc. 's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Indivior Pharmaceuticals, Inc. 's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.